SEOUL, KOREA, OCT.21, 2017 -- TESSLIFT CO., LTD., a leading provider of tissue approximation technologies for Plastic & Reconstruction markets, announced today that it has signed an exclusive agreement to distribute and market its premium mesh suspension system for tissue approximation, TESSLIFT®, with ZISHEL GROUP, an international key player in healthcare and aesthetics market.
TESSLIFT, the premium mesh implant, is deployed into the SMAS layers to suspend the surrounding tissues via tissue ingrowths technology into its pores. The barbs in the implant provides the initial holding strength to suspend the tissues. The mesh and its tissue ingrowth of the surrounding tissues provide the major contributions in the later phases. This world's first innovative technology is protected under the intellectual property rights in over 42 countries.
Mr. Hee-Dong Jang, Chief Executive Officer and Dr. Min Kim, Chief Medical Officer of TESSLIFT , commented "We are proud to add ZISHEL GROUP to our growing network of partners. They help us grow and sustain our network. Their expertise on medical innovations and medical marketing excellence, combined with their market knowledge will help us focus in the R&D and quality manufacturing."
ABOUT ZISHEL GROUP
ZISHEL GROUP is established to R&D, market, and distribute the novel medical technologies for Plastic and Reconstruction and Aesthetics. In connection with more than 23 international medical chains and +11450 private clinics, we have the mega-size distribution channels in over 52 countries covered by +35 blockbuster distributors worldwide. The majority of our executives were both educated and trained in the United States. They lead with excellence via unique leadership styles over our staffs and have propitious relationships with internationally recognized professors, physicians, and healthcare professionals worldwide. Our key differentiator is our continual investments for R&D activities under variety of applications. In the fast-changing healthcare environment, we challenge ourselves to adapt to new trends and lead developments for novel solutions tailored to our clients' needs.
WEBSITE. www.zishel.com | EMAIL. firstname.lastname@example.org
TESSLIFT is a privately owned medical device company, dedicated to the development and commercialization of the world's first invented mesh suspension implants. TESS is an abbreviation for Tissue Elevation Suspension System. For research initiatives underway, we desire to use our novel technology to expand its use to meet other unmet clinical needs. With that in mind, we are closely cooperating with surgeons and biomedical engineers to maximize the safety and effectiveness of our products.
WEBSITE. www.tesslift.com | EMAIL. email@example.com
EILEEN KIM, ZISHEL GROUP
CONTACT. +1-851-0186 [US]